Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
Type:
Grant
Filed:
September 2, 2020
Date of Patent:
February 27, 2024
Assignee:
Codexis, Inc.
Inventors:
Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
Abstract: Chimeric recombinant proteins for the detection of infection by Borreliella and/or diagnosis of Lyme disease are provided. Methods and devices for conducting immunoassays with the chimeric recombinant proteins are also provided.
Abstract: The present invention provides for recombinant Endo-S2 mutants (named Endo-S2 glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and/or ability to deliver a therapeutic agent.
Abstract: The present invention relates to a method of ligating a first peptide via its C-terminus to the N-terminus of a second peptide, wherein the reaction is catalyzed by an asparagine/aspartate (Asx) peptide ligase OaAEPI Cys247Ala having the amino acid sequence of SEQ ID NO: 1. Further encompassed are a method of preparing a dimer, oligomer, or multimer of one or more peptides of interest and a method of modifying or tagging the surface of a target cell by one or more peptides of interest. Also encompassed in the invention are the ligated peptides and/or tagged target cells obtainable according to any of the methods, the peptide ligase OaAEPI Cys247Ala having the amino acid sequence of SEQ ID NO: 1, as well as kits comprising said peptide ligase.
Type:
Grant
Filed:
September 12, 2017
Date of Patent:
October 24, 2023
Assignee:
NANYANG TECHNOLOGICAL UNIVERSITY
Inventors:
Bin Wu, Renliang Yang, Yee Hwa Wong, Julien Lescar, Chuan Fa Liu, James P Tam, Kien Truc Giang Nguyen, Ziqi Long
Abstract: Microorganisms are genetically engineered to produce 3-hydroxypropionate (3-HP). The microorganisms are carboxydotrophic acetogens. The microorganisms produce acetyl-coA using the Wood-Ljungdahl pathway for fixing CO/CO2. A ?-alanine pyruvate aminotransferase from a microorganism that contains such an enzyme is introduced. Additionally, an acetyl-coA carboxylase may also be introduced. The production of 3-HP can be improved. This can be effected by improved promoters or higher copy number or enzymes that are catalytically more efficient.
Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.
Abstract: Disclosed herein are recombinant polynucleotide sequences, vectors, host cells and methods for producing astaxanthin. The recombinant polynucleotide sequence is designed to provide a higher level of astaxanthin precursors via a shorter metabolic pathway, and thereby attains higher level of end products (e.g., astaxanthin) with desired stereoisomeric form and/or esterified form.
Abstract: The invention relates generally to methods for preparing recombinant nucleosomes. In particular, the invention relates to methods for ligating a histone peptide onto a fully assembled recombinant nucleosome. The invention further relates to modified core histone proteins, histone peptides to be ligated to the modified core histone proteins, and fully assembled recombinant nucleosomes and libraries of recombinant nucleosomes prepared by the methods of the invention.
Type:
Grant
Filed:
March 7, 2019
Date of Patent:
August 29, 2023
Assignee:
EPICYPHER, INC.
Inventors:
Martis William Cowles, Michael-Christopher Keogh, Jonathan M. Burg, Zu-Wen Sun
Abstract: The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.
Type:
Grant
Filed:
October 11, 2020
Date of Patent:
August 8, 2023
Assignee:
The University of Vermont and State Agricultural College
Inventors:
Christopher Francklyn, Karen M. Lounsbury, Tamara Williams
Abstract: A composition and method for preventing and treating infections caused by enveloped viruses, such as SARS-CoV-2 virus. The invention includes compounds having a catalytic domain of a glycosidase and a binding domain that binds the compound to the surface of the targeted virus. The invention also includes a pharmaceutical formulation comprising the compound and a pharmaceutically acceptable carrier to deliver the active portion of the compound to the infecting virus within an infected human or animal. The pharmaceutical formulation can be an inhalant or a nasal spray to the infected human or animal. The invention also includes methods of using a glycosidase or the catalytic part of a glycosidase to deactivate enveloped virus by removing glycans from the viral surface protein.
Type:
Grant
Filed:
July 16, 2021
Date of Patent:
August 8, 2023
Assignee:
ILLINOIS INSTITUTE OF TECHNOLOGY
Inventors:
Oscar Juarez, Karina Tuz, David Do Le Minh
Abstract: The present disclosure provides for non-viral compositions and methods for delivering nucleic acids into eukaryotic cells (e.g., stem cells) with high efficiency and low genotoxicity.
Type:
Grant
Filed:
July 19, 2018
Date of Patent:
July 18, 2023
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Abstract: Methods, systems and compositions for producing at least one light-boiling, volatile, organic product using at least a portion of one or more carbon containing substances from a non-biosynthetic process in a biosynthetic process are provided. These methods, systems and compositions are useful in reducing waste treatment load of carbon containing chemical process waste streams.
Type:
Grant
Filed:
June 14, 2019
Date of Patent:
June 13, 2023
Assignee:
INV NYLON CHEMICALS AMERICAS, LLC
Inventors:
Gary Smith, Paul S. Pearlman, Gregory S. Kirby
Abstract: Periplasmic fusion proteins comprising a binding motif attached to a C-terminus of a first protein or embedded within an amino acid sequence of the first protein, nucleic acid constructs encoding the periplasmic fusion proteins, vectors comprising the nucleic acid constructs, and methods of producing the periplasmic fusion proteins are provided. Also provided are protease deficient host cells for producing the periplasmic fusion proteins.
Type:
Grant
Filed:
March 18, 2020
Date of Patent:
June 13, 2023
Assignee:
BIO-RAD ABD SEROTEC GMBH
Inventors:
Christian-Michael Aloisius Heinz Hentrich, Francisco Ylera, Hans Joachim Knappik
Abstract: Recombinant bacterial cells are provided that comprise a stable non-canonical amino acid translation pathway. In some aspects, the bacteria comprise nucleic acids encoding a non-canonical amino acid translation pathway (e.g., a tRNA for incorporation of a non-canonical amino acid, such selenocysteine); a marker polypeptide that includes the non-canonical amino acid. Recombinant tRNA and selection marker coding sequences are likewise provided.
Type:
Grant
Filed:
February 10, 2020
Date of Patent:
May 30, 2023
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.
Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
December 27, 2022
Assignee:
Research Development Foundation
Inventors:
Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
Abstract: Ligase mutants of the following (1), (2), or (3): (1) a ligase mutant comprising an amino acid sequence showing 95% or more identity to the amino acid sequence of SEQ ID NO: 1, and having a nucleic acid-linking activity; (2) a ligase mutant comprising an amino acid sequence showing 90% or more identity to the amino acid sequence of SEQ ID NO: 2, and having a nucleic acid-linking activity; or (3) a ligase mutant comprising an amino acid sequence showing 97% or more identity to the amino acid sequence of SEQ ID NO: 3, and having a nucleic acid-linking activity, have excellent properties.
Abstract: The present disclosure relates to a synthetic Túngara frog foam composition. The synthetic Túngara frog foam composition comprises six synthetically synthesized ranaspumin proteins (RSN-1 to RSN-6) wherein only the active segments of the RSN proteins are synthesized and six synthetically synthesized polysaccharides comprising four tetrasaccharides, a heptasaccharide and a nonasaccharide. Multiple novel applications of the foam are described.
Abstract: The invention relates to archaeal pyrrolysyl tRNA synthetases lacking a nuclear localization signal and/or comprising a nuclear export signal. The invention also relates to polynucleotides encoding said pyrrolysyl tRNA synthetases, eukaryotic cells comprising said polynucleotide and tRNA acylated by the pyrrolysyl tRNA synthetase or a polynucleotide encoding such tRNA, methods utilizing said cells for preparing polypeptides comprising unnatural amino acid residues, and kits useful in said methods.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
November 8, 2022
Assignee:
European Molecular Biology Laboratory
Inventors:
Edward Lemke, Ivana Nikic, Gemma Estrada Girona, Christine Köhler